---
title: "PCOS Is Now PMOS: What the New Name Means and Which Blood Tests Diagnose It"
type: guide
url: "https://www.test-well.com/guides/pcos-is-now-pmos"
date_published: 2026-10-19
reviewed_at: 2026-10-19
---

# PCOS Is Now PMOS: What the New Name Means and Which Blood Tests Diagnose It

*In May 2026 polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome. Here is why, what did not change, and the blood work that still makes the diagnosis.*

> PMOS — polyendocrine metabolic ovarian syndrome — is the new name for PCOS, announced on 12 May 2026 by a global consensus of 56 patient and professional organisations and published in The Lancet. The name changed because “polycystic” was misleading: most people with the condition do not have abnormal ovarian cysts, and the condition is a whole-body hormonal and metabolic disorder. The diagnosis and the blood tests behind it did not change.

## Recommended tests

| Recommended | Type | Price | Why |
| --- | --- | --- | --- |
| [PCOS / PMOS Panel](https://www.test-well.com/tests/pcos-panel) | Panel (9 tests) | $240.99 | The androgen, pituitary, thyroid and metabolic tests the work-up uses, in one draw |
| [Testosterone, Free & Total](https://www.test-well.com/tests/testosterone-free-and-total) | Test | $54.99 | The core androgen measurement — total and free testosterone by mass spectrometry |
| [Egg Reserve & Fertility Test (AMH)](https://www.test-well.com/tests/amh) | Test | $74.99 | Accepted in adults as an alternative to the ultrasound criterion |
| [Insulin, Fasting](https://www.test-well.com/tests/insulin-fasting) | Test | $22.99 | Insulin resistance, the metabolic half of the condition |

All prices are cash-pay plus one $6 lab processing fee per order; physician authorization is included.

## What changed: the name, not the condition

On 12 May 2026 the condition known for nearly a century as polycystic ovary syndrome was given a new global name: **polyendocrine metabolic ovarian syndrome**, or PMOS. The change came out of a three-year consensus process led by the international guideline group, with 56 academic, clinical and patient organisations — the Endocrine Society among them — and more than 14,000 survey responses from people with the condition and the professionals who treat them. It was published in *The Lancet* the same day.

The reason is in the old name. “Polycystic” suggested a disease of ovarian cysts, when the follicles seen on ultrasound are not pathological cysts and many people with the condition have normal-looking ovaries; the companion analysis found no increase in abnormal ovarian cysts at all. Meanwhile the features that actually drive health outcomes — excess androgens, insulin resistance, weight and metabolic risk, mood, skin and fertility effects — were nowhere in the name. The result, the consensus group argued, was delayed diagnosis, fragmented care and stigma. “Polyendocrine metabolic ovarian” names the three systems involved.

A three-year transition is under way: journals, guidelines and health systems are moving to PMOS, with full adoption planned for the 2028 international guideline update. NICE has already retitled its draft guideline. You will see both names for a while, and your own records may still say PCOS. Nothing about your diagnosis, treatment or testing changes because of the name.

## How PMOS is diagnosed (the criteria did not move)

Diagnosis in adults still rests on two of three features, with other causes excluded: **irregular or absent ovulation** (cycles shorter than 21 or longer than 35 days, or fewer than eight a year), **excess androgens** — shown clinically by hirsutism, acne or androgenic hair loss, or biochemically by a raised testosterone — and **polycystic ovarian morphology** on ultrasound, for which a raised AMH is now an accepted alternative in adults. In adolescents the ultrasound and AMH criteria are not used; both irregular cycles and androgen excess are required.

“Other causes excluded” is where most of the blood work earns its place. Thyroid disease, high prolactin, non-classic congenital adrenal hyperplasia, Cushing syndrome and androgen-secreting tumours can all produce irregular cycles or androgen excess, and each is found with a specific test. A work-up that skips them can label someone with PMOS who has a different, often more treatable, condition.

## Which blood tests are used for PMOS

| Test | What it answers | Notes |
| --- | --- | --- |
| Total and free testosterone | Is there biochemical androgen excess? | Mass-spectrometry (LC-MS/MS) assays are preferred in women because immunoassays overestimate at low levels; free testosterone or the free androgen index adds sensitivity |
| SHBG | How much testosterone is biologically active | Low SHBG is typical with insulin resistance and raises free testosterone |
| DHEA-S | Adrenal androgen contribution | Markedly high values point away from PMOS toward an adrenal cause |
| LH and FSH | Pituitary pattern | A raised LH:FSH ratio is common but is no longer a diagnostic criterion; FSH also screens for ovarian insufficiency |
| Prolactin and TSH | Exclusions | High prolactin and thyroid disease both cause irregular cycles |
| 17-hydroxyprogesterone (morning, follicular) | Exclusion of non-classic CAH | Ordered by a clinician when androgens are high |
| Fasting insulin, fasting glucose, A1c | The metabolic half: insulin resistance and glucose status | Recommended at diagnosis and periodically after; HOMA-IR is calculated from insulin and glucose |
| Lipid panel | Cardiovascular risk | Recommended at diagnosis regardless of weight |
| AMH | Ultrasound alternative in adults | Not for adolescents; not used alone |

Timing matters for several of these. LH, FSH and estradiol are read on cycle day 2–4 when periods occur; testosterone and 17-hydroxyprogesterone are drawn in the morning; insulin and glucose are fasting. Hormonal contraception suppresses androgens and gonadotropins and makes the hormone results uninterpretable, so testing is done off it (typically after three months) or interpreted with that caveat.

## What the metabolic work-up adds — and why the new name emphasises it

Insulin resistance is present in a majority of people with PMOS, including many at a normal weight, and it is the mechanism behind much of the condition: high insulin drives the ovaries and adrenals to make more androgens and lowers SHBG, which raises the active fraction further. It is also what carries the long-term risks — type 2 diabetes, fatty liver, sleep apnoea and cardiovascular disease — which is why the international guideline recommends glucose testing (an oral glucose tolerance test, A1c or fasting glucose) at diagnosis and every one to three years, and a lipid panel at diagnosis.

Fasting insulin is not formally part of the diagnostic criteria, but with fasting glucose it gives HOMA-IR, a widely used estimate of insulin resistance that many clinicians track to guide lifestyle, metformin or GLP-1 decisions. The [Insulin Resistance Panel](https://www.test-well.com/tests/insulin-resistance-panel) bundles insulin, glucose and A1c for exactly that purpose; the [PCOS Panel](https://www.test-well.com/tests/pcos-panel) includes insulin and A1c alongside the hormones.

## Ordering the tests without a referral

Every test above except 17-hydroxyprogesterone can be ordered online and drawn at a Quest or Labcorp patient service center after a licensed physician reviews the order; results post to your portal in one to five business days and can be shared with your clinician. The PCOS Panel — renamed in our catalog to carry both names — covers total and free testosterone, DHEA-S, LH, FSH, prolactin, SHBG, fasting insulin, A1c and TSH in one draw. The results do not make the diagnosis on their own: the criteria require your cycle history and examination, and the exclusions are a clinical judgement. What the blood work does is arrive at that appointment with the numbers already in hand.

## Frequently asked questions

### Is PMOS the same as PCOS?

Yes. Polyendocrine metabolic ovarian syndrome is the new name for polycystic ovary syndrome, adopted in May 2026. The diagnosis, criteria and treatments are unchanged; only the name is different, and both will be used during a three-year transition.

### Why was PCOS renamed?

Because “polycystic” was inaccurate and misleading: the ovarian follicles seen in the condition are not pathological cysts, many people with it have normal ovaries, and the name said nothing about the hormonal and metabolic features that matter most. A global consensus of 56 organisations and more than 14,000 survey respondents chose a name that reflects the endocrine, metabolic and ovarian systems involved.

### What blood tests diagnose PMOS?

Total and free testosterone (ideally by mass spectrometry) with SHBG and DHEA-S for androgen excess; LH, FSH, prolactin and TSH for the pituitary pattern and exclusions; fasting insulin, glucose and A1c plus a lipid panel for the metabolic side; and AMH as an adult alternative to ultrasound. Diagnosis also requires cycle history and examination, so the tests inform the appointment rather than replace it.

### Did the diagnostic criteria change with the new name?

No. Adults are still diagnosed on two of three features — irregular ovulation, androgen excess, and polycystic ovarian morphology (or raised AMH) — with other causes excluded, per the 2023 International Evidence-based Guideline. The 2028 guideline update will carry the new name; the criteria are a separate scientific question.

### Is there a PMOS test panel?

TestWell's PCOS Panel — now listed as the PCOS / PMOS Panel — contains the standard work-up: total and free testosterone, DHEA-S, LH, FSH, prolactin, SHBG, fasting insulin, A1c and TSH. AMH and a lipid panel can be added to the same order.

### Do I need to stop birth control before PMOS blood tests?

Hormonal contraception lowers androgens and suppresses LH and FSH, so hormone results taken on it do not reflect your baseline. Clinicians generally test after about three months off hormonal contraception or interpret the results with that limitation; do not stop a method without discussing contraception and timing with your clinician first.

## Sources

- [Endocrine Society — PMOS: new name for the condition affecting 170 million women (12 May 2026)](https://www.endocrine.org/news-and-advocacy/news-room/2026/pcos-name-change)
- [The Lancet — Polyendocrine metabolic ovarian syndrome, the new name for PCOS: a multistep global consensus process (2026)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext)
- [NICE — PMOS (previously PCOS): assessment and management, draft guideline (July 2026)](https://www.nice.org.uk/guidance/gid-ng10436/documents/450)
- [Teede HJ, et al. International Evidence-based Guideline for the Assessment and Management of PCOS (2023)](https://www.monash.edu/medicine/mchri/pcos/guideline)
- [NICHD (NIH) — Polycystic Ovary Syndrome: condition information](https://www.nichd.nih.gov/health/topics/pcos)

---

Medically reviewed by Youmna DiStefano, MD (Medical Reviewer, TestWell); last reviewed 2026-10-19. Review policy: https://www.test-well.com/reviewers/youmna-distefano-md

Canonical page: https://www.test-well.com/guides/pcos-is-now-pmos
Machine-readable catalog: https://www.test-well.com/api/catalog.json · MCP server: https://www.test-well.com/mcp · Overview for agents: https://www.test-well.com/llms.txt

Prices are cash-pay, in USD, and include physician authorization; every order adds one flat $6 lab processing fee. Educational content is not a diagnosis — discuss results with a clinician.